Company Profile

ImmunoGen, Inc. is a commercial-stage biotechnology company. The Company is focused on developing and commercializing of antibody- drug conjugates (ADCs) to improve outcomes for cancer patients. An ADC with the Company's technology comprises an antibody that binds to a target found on tumor cells and is conjugated to one of its potent anti-cancer agents as a payload to kill the tumor cell once the ADC has bound to its target. Its ELAHERE (Mirvetuximab Soravtansine) is a first-in-class ADC targeting folate receptor alpha (FRa), a cell-surface protein over-expressed in a number of epithelial tumors, including ovarian, endometrial, and non-small-cell lung cancers. Its Pivekimab sunirine (PVEK), is an ADC comprised of a high-affinity antibody designed to target CD123 with site-specific conjugation. The Company is advancing PVEK in clinical trials for patients with blastic plasmacytoid dendritic cell neoplasm (BPDCN) and acute myeloid leukemia (AML).

Employees

277

Sector

Biotechnology & Medical Research

More about the company

21/24/21	AbbVie CEO to Retire; COO Robert Michael Named Successor	MT
13/24/13	BioPharma Credit gets USD50.6 million from Abbvie's ImmunoGen purchase	AN
13/24/13	Biopharma Credit Secures $51 Million Loan Repayment from US Biotech ImmunoGen	MT
13/24/13	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Global BMI Index	CI
13/24/13	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P TMI Index	CI
13/24/13	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from S&P Biotechnology Select Industry Index	CI
12/24/12	Top Stories at Midday: Bezos Sells Nearly 12 Million Amazon Shares; Diamondback's $26 Billion Endeavor Energy Deal; Citigroup's Risk Management Procedures Rebuked; AbbVie Buys ImmunoGen	MT
12/24/12	AbbVie Completes $10.1 Billion Acquisition of ImmunoGen, Lowers Q1 Adjusted EPS Guidance	MT
12/24/12	AbbVie: acquisition of ImmunoGen finalized
12/24/12	AbbVie Acquires ImmunoGen for $31.26 per Share	MT
12/24/12	Immunogen, Inc. Announces Board Changes	CI
12/24/12	ImmunoGen, Inc.(NasdaqGS:IMGN) dropped from NASDAQ Composite Index	CI
12/24/12	AbbVie Inc. completed the acquisition of ImmunoGen, Inc. from Redmile Group, LLC, RA Capital Management, L.P., BlackRock, Inc., State Street Corporation, The Vanguard Group, Inc. and others.	CI

04/23/04	Piper Sandler Downgrades ImmunoGen to Neutral From Overweight, Raises Price Target to $31 From $24	MT
01/23/01	Barclays Downgrades ImmunoGen to Equalweight From Overweight, Raises Price Target to $31 From $27	MT
01/23/01	Deutsche Bank Downgrades ImmunoGen to Hold From Buy, Adjusts Price Target to $31 From $25	MT
01/23/01	BMO Capital Downgrades ImmunoGen to Market Perform From Outperform, Price Target is $31	MT
01/23/01	Guggenheim Downgrades ImmunoGen to Neutral From Buy, Adjusts Price Target to $31 From $25	MT

12/24/12	AbbVie Completes Acquisition of ImmunoGen	PR
02/24/02	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
04/24/04	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(4)	AQ
04/24/04	ImmunoGen Announces Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)	BU
10/23/10	ImmunoGen Presents Findings from Newly Diagnosed Acute Myeloid Leukemia Cohorts in Phase 1b/2 Study of Pivekimab Sunirine in Combination with Azacitidine and Venetoclax at ASH	BU

12/24/12	Diamondback Energy : Abbvie, Diamondback Energy, Gilead...les valeurs à suivre aujourd'hui à Wall Street
12/24/12	Abbvie : abaisse ses perspectives après le rachat d'Immunogen
12/24/12	AbbVie : acquisition d'ImmunoGen finalisée
02/24/02	Omzetdaling Abbvie valt mee
22/24/22	HBM bleibt nach neun Monaten in den roten Zahlen

Manager	Title	Age	Since
Stacy Coen PRN	Corporate Officer/Principal	55	03/06/2020
Theresa Wingrove CTO	Chief Tech/Sci/R&D Officer	68	24/01/2011

ImmunoGen, Inc. Share Price

Stocks

IMGN

US45253H1014

Biotechnology & Medical Research

Latest news: ImmunoGen, Inc.

Analysts' recommendations: ImmunoGen, Inc.

Press Releases: ImmunoGen, Inc.

News in other languages: ImmunoGen, Inc.

Managers and Directors: ImmunoGen, Inc.

Latest insider transactions

Other Biotechnology & Medical Research

Company Profile

Date	Insider	Type	Main position	Quantity	% Market Cap.
12/02/24	Isabel Kalofonos	Issuer sale	Executive/Senior Manager	3,51,083	0.1257%
12/02/24	Tracey McCain	Issuer sale	Director	1,52,546	0.0546%
12/02/24	Renee Lentini	Issuer sale	VP & PRIN ACCTG OFFICER	2,21,353	0.0792%

Add to a list 0 selected To use this feature you must be a member Log in Sign up	Change	5-day change	1-year change	3-year change	Capi.($)
IMMUNOGEN, INC.	-.--%	+6.73%	-	-	835.91Cr
LONZA GROUP AG	+0.56%	-4.17%	-1.90%	+9.79%	4.56TCr
REVOLUTION MEDICINES, INC.	-0.01%	-1.23%	+343.25%	+544.77%	4.4TCr
IQVIA HOLDINGS INC.	+1.43%	+4.19%	+45.22%	+27.56%	4.37TCr
BEONE MEDICINES AG	-2.22%	-1.44%	+4.26%	+72.93%	4.02TCr
CELLTRION, INC.	-0.73%	-4.72%	+8.55%	+37.89%	3.19TCr
ASCENDIS PHARMA A/S	-9.44%	-11.36%	-	-	1.74TCr
MEDPACE HOLDINGS, INC.	+4.30%	+4.93%	+24.90%	+121.44%	1.66TCr
EUROFINS SCIENTIFIC SE	+1.83%	+2.63%	+15.14%	+33.31%	1.45TCr
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-0.21%	-2.55%	+79.72%	+31.62%	1.3TCr
Average	-0.44%	-1.81%	+64.89%	+109.91%	2.97TCr
Weighted average by Cap.	-0.34%	-2.09%	+76.53%	+130.87%